Evaluation of colonoscopic findings in patients undergoing colonoscopy due to positive fecal occult blood test: a single center experience

Yıl 2021, Cilt: 4 Sayı: 5, 646 - 649, 05.09.2021

Tolga Düzenli , Mevlut Kiyak

https://doi.org/10.32322/jhsm.981855

Öz

Aim: Fecal occult blood test is used in the early diagnosis of colorectal cancers. We aimed to evaluate the colonoscopic and pathological findings of patients who underwent colonoscopy due to positive fecal occult blood test in a tertiary center.
Material and Method: Patients who had a positive fecal occult blood test and referred to the xxx Training and Research Hospital endoscopy unit for colonoscopy were included in this study. Age, gender, colonoscopic findings and pathology results of the patients were recorded. Statistical analyzes were performed with SPSS.
Results: Two hundred and twenty three patients were included in the current study. Of the patients, 101 (45.3%) were male and 122 (54.7%) were female, with a mean age of 53.2 (18-90 years). Endoscopic diagnoses were as 49 (22%) polyps, 13 (5.8%) colon cancer, 4 (1.8%) inflammatory bowel disease, 15 (6.7%) diverticulum, 63 (28.3%) perianal disease, 79 (35.4%) normal colonoscopic findings. Pathological features of colon polyps were as; tubular adenoma in 51%, tubulovillous adenoma in 18.4%, serrated adenoma in 2%, and hyperplastic polyp in 28.6%. Colonoscopy findings of patients according to age groups (over and under 50 years of age); the incidence of polyps (p=0.01) and diverticulum (p=0.001) were significantly higher in patients older than 50 years, while perianal diseases (p=0.031) and normal colonoscopic findings (p=0.008) were higher in patients younger than 50 years of age.
Conclusion: Colon pathology was detected in approximately 2/3 of the patients presenting with a positive fecal occult blood test. This test is an inexpensive, easily applicable method that helps to detect colon cancer and precursor lesions, as well as pathologies such as subclinical inflammatory bowel disease and diverticulum causing chronic blood loss.

Anahtar Kelimeler

colonoscopy, colorectal cancer, fecal occult blood test, polyp

Proje Numarası

YOKTUR.

Kaynakça

• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021; 14: 101174.
• Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019; 394: 1467-80.
• TC SB Halk Sağlığı Genel Müdürlüğü Kolorektal Kanser Tarama Programı Ulusal Standartları. https://hsgm.saglik.gov.tr/tr/kanser-tarama-standartlari/listesi/kolorektal-kanser-tarama-program%C4%B1-ulusal-standartlar%C4%B1.html (access date: 08.08.2021).
• Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Anaesthesiol 2010; 24: 417-25.
• Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009; 361: 1179-87.
• Kara M, Tanoglu A. Screening strategies in a global public health issue colorectal carcinoma and place of colonoscopy. TAF Prev Med Bull 2013; 12: 743-50.
• Utku OG, Ergul B, Oguz D. Gaitada gizli kan testi pozitifliği nedeni ile kolonoskopi yapılan hastaların kolonoskopik ve patolojik sonuçlarının değerlendirilmesi. Akademik Gastroenteroloji Derg 2018; 17: 17-20.
• Lauby-Secretan B, Vilahur N, Bianchini F, et al. The IARC perspective on colorectal cancer screening. N Engl J Med 2018; 378: 1734-40.
• Tanaka K, Sobue T, Zha L, et al. Effectiveness of screening using fecal occult blood test and colonoscopy on the risk of colorectal cancer: The Japan Public Health Center-based prospective study. J Epidemiol 2021; 10.2188/jea.JE20210057.
• Qaseem A, Crandall CJ, Mustafa RA, et al. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians. Ann Intern Med 2019; 171: 643-54.
• Mayir B, Ensari CÖ, Durhan A, Çöpelci Y. Kolorektal kanser tarama amaçlı yapılan gaytada gizli kan testi pozitif saptanan hastalarda kolonoskopi bulguları. Turk J Colorectal Dis 2018; 28: 27-30.
• Akkuzu MZ, Sezgin O, Üçbilek E, et al. Gaitada gizli kan pozitifliği nedeniyle kolonoskopi yapılanlarda kolorektal malignite sıklığı. MKÜ Tıp Derg 2020; 11: 109-12.
• Kara Y, Sarıcı İŞ, Kalaycı MU. Bölgemizde yürütülen kolon kanser tarama programının etkinliğinin değerlendirilmesi. İstanbul Kanuni Sultan Süleyman Tıp Derg 2019; 11: 31-6.
• Hultcrantz R. Aspects of colorectal cancer screening, methods, age and gender. J Intern Med 2021; 289: 493-507.
• Kamis F, Tanoglu A, Unal Cetin E, Beyazit Y, YazganY. Retrospective analysis of patients underwent colonoscopic polypectomy: A two-center study. Med Sc 2020; 9: 473-7.
• Bevan R, Rutter MD. Colorectal cancer screening-who, how, and when? Clin Endosc 2018; 51: 37-49.
• Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst 2017; 109: djw322. 
• Vuik FE, Nieuwenburg SA, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-6. 
• Saad El Din K, Loree JM, Sayre EC, et al. Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. BMC Cancer 2020; 20: 288.
• Lee MW, Pourmorady JS, Laine L. Use of fecal occult blood testing as a diagnostic tool for clinical indications: a systematic review and meta-analysis. Am J Gastroenterol 2020; 115: 662-70.